Orbimed Advisors Llc Sells 5,000 Shares of Audentes Therapeutics, Inc. (BOLD) Stock

Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 5,000 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $22.35, for a total value of $111,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Audentes Therapeutics, Inc. (BOLD) opened at 24.28 on Wednesday. Audentes Therapeutics, Inc. has a 52 week low of $13.13 and a 52 week high of $24.50. The stock’s market capitalization is $674.60 million. The company has a 50-day moving average price of $24.35 and a 200 day moving average price of $16.88.

Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.10). Equities analysts forecast that Audentes Therapeutics, Inc. will post ($3.53) EPS for the current fiscal year.

WARNING: “Orbimed Advisors Llc Sells 5,000 Shares of Audentes Therapeutics, Inc. (BOLD) Stock” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/13/orbimed-advisors-llc-sells-5000-shares-of-audentes-therapeutics-inc-bold-stock.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its position in Audentes Therapeutics by 278.5% during the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 5,700 shares during the period. Nationwide Fund Advisors lifted its position in Audentes Therapeutics by 288.9% during the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 6,384 shares during the period. Citadel Advisors LLC acquired a new stake in Audentes Therapeutics during the 1st quarter worth about $184,000. State of Wisconsin Investment Board acquired a new stake in Audentes Therapeutics during the 2nd quarter worth about $210,000. Finally, Rhumbline Advisers acquired a new stake in Audentes Therapeutics during the 2nd quarter worth about $252,000. 77.01% of the stock is owned by institutional investors.

BOLD has been the topic of several recent research reports. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Monday, July 17th. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Finally, Evercore ISI initiated coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Audentes Therapeutics has a consensus rating of “Hold” and an average target price of $22.40.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply